Eli Lilly and Novo Nordisk Compete in Weight Loss Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: NASDAQ.COM
- Market Leadership: Eli Lilly leads the weight loss market with a remarkable 56% year-over-year revenue increase to $19.8 billion in Q1, while its EPS soared 170% to $8.26, showcasing its strong performance in chronic weight management and solidifying its market share.
- Product Line Expansion: Eli Lilly's weight loss drug Zepbound has become the best-seller in this niche, and the newly approved oral GLP-1 therapy Foundayo is attracting patients hesitant about injectable drugs, which is expected to expand its addressable market and enhance its customer base.
- Changing Competitive Dynamics: Novo Nordisk is regaining competitiveness in the weight loss market, with its oral Wegovy achieving over two million prescriptions since launch, and the newly approved high-dose Wegovy is likely to enhance its market share, helping it compete with Eli Lilly's Zepbound.
- Future Potential: Although Novo Nordisk's forward P/E of 13 appears more attractive than Eli Lilly's 31.3, Eli Lilly is still viewed as the more valuable investment due to its diversified product portfolio and dominant position in the weight loss sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1112.000
Low
950.00
Averages
1192
High
1500
Current: 1112.000
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk to Seek Approval for Weight-Loss Pill Soon
- Increased Market Competition: CEO Mike Doustdar announced that Novo Nordisk plans to seek Chinese regulatory approval for its weight-loss pill “very soon,” aiming to catch up with rival Eli Lilly's leading position in the world's second-largest pharmaceutical market.
- Strategic Positioning: This move not only reflects Novo Nordisk's commitment to the Chinese market but also indicates its intention to meet the growing health demands through the launch of its weight-loss medication, thereby enhancing its market share in the rapidly evolving pharmaceutical industry.
- Industry Outlook: With rising concerns over obesity in China, the weight-loss medication market holds significant potential, and Novo Nordisk's application is expected to drive product line diversification and improve overall performance in the future.
- Regulatory Challenges: While Novo Nordisk is actively advancing the approval process, the complex drug regulatory environment in China means that successfully obtaining approval will be a critical factor for the company's success in this market.
See More
Cathie Wood Resumes Buying After IPO Surge
- Eli Lilly Performance: Despite a 1.43% drop on Wednesday, Eli Lilly (LLY) has surged 40% over the past year, briefly exceeding a $1 trillion market cap, driven by strong growth in GLP-1 drugs, with 2023 revenue expected to rise by 26% to 30%.
- Block's Current Status: Block (XYZ) shares rose 2.75%, with a market cap of $43 billion; although its stock has been flat over the past year, revenue growth has accelerated over the last four quarters, indicating future growth potential, and the current high P/E ratio offers a good entry point for investors.
- Coinbase's Challenges: Coinbase (COIN) shares fell 2.33%, with a 37% decline over the past year due to weak demand for Bitcoin and other cryptocurrencies, leading to a 22% and 31% drop in revenue over the last two quarters, with profitability expected to decline sharply for the second consecutive year.
- Investment Strategy Analysis: Cathie Wood resumed buying after four days of selling, adding to positions in stocks like Eli Lilly, Block, and Coinbase, reflecting her strategy of seeking investment opportunities during market volatility, particularly by increasing stakes when prices drop to achieve higher returns.
See More
Recap of CNBC Investing Club Monthly Meeting
- Portfolio Analysis: During the June Monthly Meeting, Jim Cramer and Jeff Marks provided an in-depth analysis of 35 portfolio stocks, highlighting their preference for Intel due to its significant upside potential in data center CPU growth, particularly in the context of competition with TSMC.
- Tech Giants Restructuring: Cramer noted a reordering of the 'Magnificent Seven,' with newcomers like SpaceX and the yet-to-go-public Anthropic and OpenAI emerging as formidable competitors, indicating intensified market competition, especially in the AI sector.
- Strengths of Alphabet and Apple: Alphabet is positioned advantageously in the AI era with its YouTube and Waymo businesses, while Apple leverages its ecosystem of over 2.5 billion iPhone users to strengthen its AI partnership with Alphabet, showcasing both companies' robust market positions.
- Market Dynamics and Investment Strategy: Despite challenges faced by Meta and Microsoft, Cramer advises maintaining investments in Amazon and Nvidia, believing that the latter's GPU demand will continue to grow, and that Amazon's cloud business remains highly profitable.
See More
MoonLake Immunotherapeutics Set for Key Clinical Data Release
- Clinical Trial Progress: MoonLake's two large late-stage trials for hidradenitis suppurativa involved approximately 838 patients, with one trial meeting its primary goal while the other narrowly missed due to an unusually high placebo response rate, highlighting the complexity of clinical outcomes.
- Data Release Expectations: Full 52-week results from both trials are anticipated in Q2 2026, which will help assess the drug's long-term efficacy and could significantly impact future market performance.
- Acquisition Rumors: Merck is viewed as a potential acquirer of MoonLake, having made a non-binding offer exceeding $3 billion in 2025, which was rejected by MoonLake, yet discussions may resume, indicating strong market interest in the company.
- Investor Sentiment Shift: Over the past 24 hours, retail sentiment around MLTX shifted from 'bearish' to 'bullish', with message volume rising significantly, reflecting investor optimism regarding the upcoming clinical data, which could drive stock price increases.
See More
Novo Nordisk to File for Wegovy Approval in China Soon
- Market Expansion Plans: Novo Nordisk's CEO Mike Doustdar announced that the company will submit its Wegovy weight-loss pill for regulatory approval in China within a few months, indicating its intent to expand in the world's second-largest market and compete with Eli Lilly's orforglipron.
- Product Launch Context: Wegovy was launched in the U.S. earlier this year after receiving FDA approval in December, and Novo Nordisk aims to mitigate potential impacts on its GLP-1 franchise from the upcoming patent expiry of semaglutide, the active ingredient in its diabetes therapies, by introducing Wegovy in China.
- Competitive Advantage Analysis: Doustdar noted that one barrier to entry for Wegovy will be the scaling of production capabilities, suggesting that not many competitors will have the necessary capacity, which could provide Novo Nordisk with a strategic edge in the Chinese market.
- Industry Dynamics Observation: Eli Lilly submitted its marketing application for its oral GLP-1 therapy orforglipron to Chinese regulators at the end of last year, highlighting the intensifying competition in this sector, and Novo Nordisk's timely application will help position it effectively in the market.
See More
Market Volatility and Portfolio Performance Overview
- Market Volatility Overview: The S&P 500 experienced significant volatility over the past three weeks, recording its worst session in eight months on June 5, just after reaching record highs, indicating shifts in market sentiment and investor uncertainty.
- Portfolio Performance: Among 34 stocks, 19 have risen since the May meeting, with Arm's stock soaring 38.2% driven by strong AI demand and the release of a new Nvidia chip, highlighting the potential for a rebound in tech stocks.
- Bank Stocks Recovery: Wells Fargo's shares increased by 13.9%, reflecting the financial sector's status as the best-performing group in the S&P 500, although it remains down nearly 7% year-to-date, suggesting a cautious recovery amid potential earnings volatility.
- Underperforming Stocks: Amazon's stock fell 10.8%, primarily due to concerns over AI investments, despite securing a $17.5 billion loan for AI development, raising questions about its future financial health and investor confidence.
See More
Novo Nordisk to Seek Approval for Weight-Loss Pill Soon
- Increased Market Competition: CEO Mike Doustdar announced that Novo Nordisk plans to seek Chinese regulatory approval for its weight-loss pill “very soon,” aiming to catch up with rival Eli Lilly's leading position in the world's second-largest pharmaceutical market.
- Strategic Positioning: This move not only reflects Novo Nordisk's commitment to the Chinese market but also indicates its intention to meet the growing health demands through the launch of its weight-loss medication, thereby enhancing its market share in the rapidly evolving pharmaceutical industry.
- Industry Outlook: With rising concerns over obesity in China, the weight-loss medication market holds significant potential, and Novo Nordisk's application is expected to drive product line diversification and improve overall performance in the future.
- Regulatory Challenges: While Novo Nordisk is actively advancing the approval process, the complex drug regulatory environment in China means that successfully obtaining approval will be a critical factor for the company's success in this market.
See More
Cathie Wood Resumes Buying After IPO Surge
- Eli Lilly Performance: Despite a 1.43% drop on Wednesday, Eli Lilly (LLY) has surged 40% over the past year, briefly exceeding a $1 trillion market cap, driven by strong growth in GLP-1 drugs, with 2023 revenue expected to rise by 26% to 30%.
- Block's Current Status: Block (XYZ) shares rose 2.75%, with a market cap of $43 billion; although its stock has been flat over the past year, revenue growth has accelerated over the last four quarters, indicating future growth potential, and the current high P/E ratio offers a good entry point for investors.
- Coinbase's Challenges: Coinbase (COIN) shares fell 2.33%, with a 37% decline over the past year due to weak demand for Bitcoin and other cryptocurrencies, leading to a 22% and 31% drop in revenue over the last two quarters, with profitability expected to decline sharply for the second consecutive year.
- Investment Strategy Analysis: Cathie Wood resumed buying after four days of selling, adding to positions in stocks like Eli Lilly, Block, and Coinbase, reflecting her strategy of seeking investment opportunities during market volatility, particularly by increasing stakes when prices drop to achieve higher returns.
See More
Recap of CNBC Investing Club Monthly Meeting
- Portfolio Analysis: During the June Monthly Meeting, Jim Cramer and Jeff Marks provided an in-depth analysis of 35 portfolio stocks, highlighting their preference for Intel due to its significant upside potential in data center CPU growth, particularly in the context of competition with TSMC.
- Tech Giants Restructuring: Cramer noted a reordering of the 'Magnificent Seven,' with newcomers like SpaceX and the yet-to-go-public Anthropic and OpenAI emerging as formidable competitors, indicating intensified market competition, especially in the AI sector.
- Strengths of Alphabet and Apple: Alphabet is positioned advantageously in the AI era with its YouTube and Waymo businesses, while Apple leverages its ecosystem of over 2.5 billion iPhone users to strengthen its AI partnership with Alphabet, showcasing both companies' robust market positions.
- Market Dynamics and Investment Strategy: Despite challenges faced by Meta and Microsoft, Cramer advises maintaining investments in Amazon and Nvidia, believing that the latter's GPU demand will continue to grow, and that Amazon's cloud business remains highly profitable.
See More
MoonLake Immunotherapeutics Set for Key Clinical Data Release
- Clinical Trial Progress: MoonLake's two large late-stage trials for hidradenitis suppurativa involved approximately 838 patients, with one trial meeting its primary goal while the other narrowly missed due to an unusually high placebo response rate, highlighting the complexity of clinical outcomes.
- Data Release Expectations: Full 52-week results from both trials are anticipated in Q2 2026, which will help assess the drug's long-term efficacy and could significantly impact future market performance.
- Acquisition Rumors: Merck is viewed as a potential acquirer of MoonLake, having made a non-binding offer exceeding $3 billion in 2025, which was rejected by MoonLake, yet discussions may resume, indicating strong market interest in the company.
- Investor Sentiment Shift: Over the past 24 hours, retail sentiment around MLTX shifted from 'bearish' to 'bullish', with message volume rising significantly, reflecting investor optimism regarding the upcoming clinical data, which could drive stock price increases.
See More
Novo Nordisk to File for Wegovy Approval in China Soon
- Market Expansion Plans: Novo Nordisk's CEO Mike Doustdar announced that the company will submit its Wegovy weight-loss pill for regulatory approval in China within a few months, indicating its intent to expand in the world's second-largest market and compete with Eli Lilly's orforglipron.
- Product Launch Context: Wegovy was launched in the U.S. earlier this year after receiving FDA approval in December, and Novo Nordisk aims to mitigate potential impacts on its GLP-1 franchise from the upcoming patent expiry of semaglutide, the active ingredient in its diabetes therapies, by introducing Wegovy in China.
- Competitive Advantage Analysis: Doustdar noted that one barrier to entry for Wegovy will be the scaling of production capabilities, suggesting that not many competitors will have the necessary capacity, which could provide Novo Nordisk with a strategic edge in the Chinese market.
- Industry Dynamics Observation: Eli Lilly submitted its marketing application for its oral GLP-1 therapy orforglipron to Chinese regulators at the end of last year, highlighting the intensifying competition in this sector, and Novo Nordisk's timely application will help position it effectively in the market.
See More
Market Volatility and Portfolio Performance Overview
- Market Volatility Overview: The S&P 500 experienced significant volatility over the past three weeks, recording its worst session in eight months on June 5, just after reaching record highs, indicating shifts in market sentiment and investor uncertainty.
- Portfolio Performance: Among 34 stocks, 19 have risen since the May meeting, with Arm's stock soaring 38.2% driven by strong AI demand and the release of a new Nvidia chip, highlighting the potential for a rebound in tech stocks.
- Bank Stocks Recovery: Wells Fargo's shares increased by 13.9%, reflecting the financial sector's status as the best-performing group in the S&P 500, although it remains down nearly 7% year-to-date, suggesting a cautious recovery amid potential earnings volatility.
- Underperforming Stocks: Amazon's stock fell 10.8%, primarily due to concerns over AI investments, despite securing a $17.5 billion loan for AI development, raising questions about its future financial health and investor confidence.
See More
